“The target organs for istradefylline in rats and dogs are consistent and are the adrenal gland (hypertrophy/hyperplasia) and lung (pneumonitis with septal thickening).”
✓ VerifiedFDA pharmacology/toxicology review, p. 29Source ↗
Why that species
No novel human metabolites relative to rat and dog
“In human studies, MI was the primary metabolite and no novel metabolites were identified when compared to the rat and dog data.”
✓ VerifiedFDA pharmacology/toxicology review, p. 39Source ↗
Surrogate molecule
No surrogate; the clinical compound was tested
“Brain mineralization was not detected in mice administered istradefylline (0, 25, 125, or 250 mg/kg/day) orally for two years or in dogs administered istradefylline (0, 10, 30, or 100 mg/kg/day) orally for 52 weeks.”
“The target organs for istradefylline in rats and dogs are consistent and are the adrenal gland (hypertrophy/hyperplasia) and lung (pneumonitis with septal thickening).”
✓ VerifiedFDA pharmacology/toxicology review, p. 29Source ↗
Species: DART
Rat (fertility, teratology) and rabbit (embryo-fetal, alone and with levodopa/carbidopa)
“The NOAEL is 160 mg/kg/d for this rat fertility study. A rabbit embryo-fetal study was conducted in combination with levodopa/carbidopa.”
✓ VerifiedFDA pharmacology/toxicology review, p. 144Source ↗
Species: carcinogenicity
Mouse and rat (lifetime oral studies)
“In lifetime oral carcinogenicity studies, there was no evidence of carcinogenicity in mouse (0, 25, 125, or 250 mg/kg) or rat (0, 30, 100, or 320 mg/kg).”
No surrogate used; istradefylline tested directly in mouse, rat and dog
“Brain mineralization was not detected in mice administered istradefylline (0, 25, 125, or 250 mg/kg/day) orally for two years or in dogs administered istradefylline (0, 10, 30, or 100 mg/kg/day) orally for 52 weeks.”